<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34119273</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2653</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</Title><ISOAbbreviation>J Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>232</StartPage><EndPage>236</EndPage><MedlinePgn>232-236</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jocn.2021.05.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0967-5868(21)00227-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The relationship between reserve of L-carnitine and severity in patients with Amyotrophic lateral sclerosis (ALS) is not studied sufficiently. We decided to measure the serum levels of L-carnitine in patients and the relationship with ALS severity.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This cross-sectional study evaluated the serum levels of L-carnitine in 30 patients with ALS (total-case) divided into two groups included 15 patients in the Oral-Fed (OF) group and 15 patients in the Enteral-Fed (EF) group, compared with 15 healthy people matched in age and sex in the control group. We measured the body mass index (BMI), daily intake of L-carnitine, amyotrophic lateral sclerosis functional rating scale (ALSFRS), and serum L-carnitine level in all participants and compared among groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum L-carnitine (p&#xa0;&lt;&#xa0;0.001) and BMI (p&#xa0;=&#xa0;0.03) were significantly lower in the total-case group compared to the control group. Alternatively, the serum level of L-carnitine (p&#xa0;=&#xa0;0.001), ALSFRS (p&#xa0;&lt;&#xa0;0.001), BMI (p&#xa0;=&#xa0;0.007), and dietary L-carnitine intake (p&#xa0;=&#xa0;0.002) were significantly higher in OF group compared with EF. Higher serum L-carnitine levels were associated with a higher score of ALSFRS (&#x3b2;&#xa0;=&#xa0;0.46, P&#xa0;=&#xa0;0.01) in the total-case group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study's results showed that serum levels of L-carnitine were lower in patients with ALS in comparison to healthy people. Also, the lower serum level of L-carnitine was associated with the higher severity of the disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarraf</LastName><ForeName>Payam</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bitarafan</LastName><ForeName>Sama</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Bitarafans@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nafissi</LastName><ForeName>Shahriar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fathi</LastName><ForeName>Davood</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abaj</LastName><ForeName>Faezeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asl Motallebnejad</LastName><ForeName>Zoya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teimouri</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahedi</LastName><ForeName>Kolsoom</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Clin Neurosci</MedlineTA><NlmUniqueID>9433352</NlmUniqueID><ISSNLinking>0967-5868</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7UI8SM58A</RegistryNumber><NameOfSubstance UI="D002331">Carnitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002331" MajorTopicYN="N">Carnitine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004435" MajorTopicYN="N">Eating</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ALSFRS</Keyword><Keyword MajorTopicYN="N">Amyotrophic Lateral Sclerosis Functional Rating Scale</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">L-carnitine</Keyword><Keyword MajorTopicYN="N">Serum level</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>13</Day><Hour>20</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34119273</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2021.05.017</ArticleId><ArticleId IdType="pii">S0967-5868(21)00227-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>